Molecular docking and in silico adme(t) evaluation of selective phytochemical inhibitors of vegf2 target for the treatment of diabetic retinopathy

Abstract

Diabetic retinopathy (DR) is the leading cause of vision loss in diabetic patients. Currently, the treatment involves the use of glucocorticoids or a VEGF antagonist, which are “off-label” at present. However, the conventional method of drug discovery and development is a time-consuming process that requires more than a decade of meticulous research and huge financial support. While there are a few effective small organic molecules against DR that were identified many years ago, nutraceuticals - naturally available functional foods containing vitamins, antioxidants, minerals, fatty acids, and amino acids - can also help delay the progression of some diseases.